PRALSETINIB for Cholangiocarcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 8 adverse event reports in the FDA FAERS database where PRALSETINIB was used for Cholangiocarcinoma.
Most Reported Side Effects for PRALSETINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 126 | 8.9% | 126 | 8 |
| Fatigue | 104 | 7.3% | 5 | 19 |
| Asthenia | 96 | 6.8% | 11 | 33 |
| Off label use | 92 | 6.5% | 12 | 16 |
| Hypertension | 89 | 6.3% | 10 | 23 |
| Disease progression | 85 | 6.0% | 54 | 23 |
| Anaemia | 80 | 5.6% | 3 | 37 |
| Diarrhoea | 79 | 5.6% | 7 | 31 |
| Pyrexia | 75 | 5.3% | 7 | 47 |
| White blood cell count decreased | 74 | 5.2% | 4 | 31 |
| Blood pressure increased | 73 | 5.1% | 3 | 23 |
| Constipation | 72 | 5.1% | 3 | 23 |
| Pneumonia | 62 | 4.4% | 12 | 46 |
| Platelet count decreased | 50 | 3.5% | 3 | 24 |
| No adverse event | 46 | 3.2% | 0 | 0 |
Other Indications for PRALSETINIB
Lung neoplasm malignant (517)
Non-small cell lung cancer (270)
Thyroid cancer (199)
Product used for unknown indication (152)
Medullary thyroid cancer (48)
Lung adenocarcinoma (38)
Non-small cell lung cancer metastatic (31)
Bronchial carcinoma (17)
Thyroid cancer metastatic (17)
Lung adenocarcinoma stage iv (15)
Other Drugs Used for Cholangiocarcinoma
GEMCITABINE (1,181)
CISPLATIN (923)
CAPECITABINE (608)
DURVALUMAB (444)
OXALIPLATIN (441)
PEMIGATINIB (431)
FLUOROURACIL (341)
GEMCITABINE\GEMCITABINE (292)
IVOSIDENIB (277)
NIVOLUMAB (250)